J
Joel W. Slaton
Researcher at University of Oklahoma
Publications - 8
Citations - 300
Joel W. Slaton is an academic researcher from University of Oklahoma. The author has contributed to research in topics: Bladder cancer & Alvimopan. The author has an hindex of 4, co-authored 8 publications receiving 266 citations.
Papers
More filters
Journal ArticleDOI
Alvimopan accelerates gastrointestinal recovery after radical cystectomy: A multicenter randomized placebo-controlled trial
Cheryl T. Lee,Sam S. Chang,Ashish M. Kamat,Gilad E. Amiel,Timothy L. Beard,Amr Fergany,R. Jeffrey Karnes,Andrea Kurz,Venu Menon,Wade J. Sexton,Joel W. Slaton,Robert S. Svatek,Shandra Wilson,Lee Techner,Richard Bihrle,Gary D. Steinberg,Michael O. Koch +16 more
TL;DR: Alvimopan is a useful addition to a standardized care pathway in patients undergoing radical cystectomy for bladder cancer by accelerating GI recovery and shortening LOS, with a safety profile similar to placebo.
Journal ArticleDOI
Alvimopan, a peripherally acting μ-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: Economic analysis of a phase 4 randomized, controlled trial
Teresa L. Kauf,Robert S. Svatek,Gilad E. Amiel,Timothy L. Beard,Sam S. Chang,Amr Fergany,R. Jeffrey Karnes,Michael O. Koch,Jerome F. O'Hara,Cheryl T. Lee,Wade J. Sexton,Joel W. Slaton,Gary D. Steinberg,Shandra Wilson,Lee Techner,Carolyn Martin,Jessica Moreno,Ashish M. Kamat +17 more
TL;DR: In patients treated with radical cystectomy alvimopan decreased hospitalization cost by reducing the health care services associated with postoperative ileus and decreasing the hospital stay.
Journal ArticleDOI
Phosphatidylserine targeted single-walled carbon nanotubes for photothermal ablation of bladder cancer
Needa A. Virani,Carole A. Davis,Patrick McKernan,Paul J. Hauser,Robert E. Hurst,Joel W. Slaton,Ricardo Prada Silvy,Daniel E. Resasco,Roger G. Harrison +8 more
TL;DR: In a short-term efficacy study in mice with orthotopic MB49 murine bladder tumours treated with the SWCNT-AV conjugate and NIR light, no tumours were visible on the bladder wall 24 h after N IR light treatment, and there was no damage to the bladder.
Journal ArticleDOI
Phase Ib/II study of an IL-2/T-cell receptor fusion protein in combination with gemcitabine and cisplatin in advanced or metastatic chemo-refractory urothelial cancer (UC).
Mayer Fishman,Daniel A. Vaena,Parminder Singh,Joel Picus,Ulka N. Vaishampayan,Joel W. Slaton,John Francis Mahoney,Sanjiv S. Agarwala,Charles J. Rosser,Danny Landau,Julio Hajdenberg,Peter J. Van Veldhuizen,Rahul A. Parikh,Sarah Alter,Liza Hernandez,Peter R. Rhode,Hing C. Wong +16 more
TL;DR: AlT-801 demonstrated potent activity against syngeneic and xenograft UC, suggesting sensitivity of this disease to IL-2 based immunotherapy, suggesting limited therapeutic options for chemo-refractory UC.
Proceedings ArticleDOI
Orthotopic AY-27 rat bladder urothelial cell carcinoma model presented an elevated methemoglobin proportion in the increased total hemoglobin content when evaluated in vivo by single-fiber reflectance spectroscopy
TL;DR: The increased total hemoglobin and the elevation of MetHb proportion may signify angiogenesis and degradation in hemoglobin oxygen-transport, indicating disruption of subepithelium tissue architecture.